Brevicidine TFA
Based on 1 Customer Validation
Brevicidine TFA is an antimicrobial peptide with selective bactericidal activity against Gram-negative pathogens. Brevicidine TFA disrupts bacterial morphology by binding to lipopolysaccharide (LPS) on the bacterial cell membrane to form pores. Brevicidine TFA causes dissipation of intracellular proton motive force, outer membrane damage, inhibition of ATP biosynthesis and reactive oxygen species accumulation in bacterial cells. As a sensitizer, Brevicidine TFA exerts synergistic activity when combined with a variety of conventional antibiotics.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 97.81%
- 分子式: C74H106N18O17·xC2HF3O2
- 分子量:1519.74 (free base)
-
保管条件:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
生物活性
Brevicidine (0-2 μM; 20 h) TFA acts as a synergistic sensitizer. When combined with outer membrane-impermeable antibiotics (Erythromycin (HY-B0220), Azithromycin (HY-17506), Vancomycin (HY-B0671)) against Acinetobacter baumannii strains, it reduces the MIC by up to 128-fold at concentrations as low as 1 μM[1].
Brevicidine (0.125-4 μM; 25 min) TFA disrupts the outer membrane of Acinetobacter baumannii ATCC 17978 in a dose-dependent manner[1].
Brevicidine (1-4 μM; 1 h) TFA inhibits ATP synthesis and induces ROS production in Acinetobacter baumannii, and this effect is enhanced when used in combination with Erythromycin[1].
Brevicidine (1-16 mg/L; 20 h) TFA selectively inhibits Gram-negative pathogenic bacteria with an MIC range of 1-16 mg/L, and shows no activity against Gram-positive pathogenic bacteria[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c (male)[1]
-
Dosage:5 mg/kg (monotherapy); 5 mg/kg (combined with 5 mg/kg Erythromycin)
-
Administration:i.v.; single dose
-
Result:Reduced the death rate of A. baumannii-infected mice from 80% to 60%; significantly reduced bacterial load in the liver and spleen.
Achieved 100% survival when combined with 5 mg/kg Erythromycin; showed greater reduction in bacterial loads across organs when combined with Erythromycin compared to monotherapy.
化学情報
-
性状 Solid
-
分子量 1519.74 (free base)
-
分子式 C74H106N18O17·xC2HF3O2
-
Color White to off-white
-
配列
4-Methylhexanoyl-{d-Asn}-{d-Tyr}-{d-Trp}-{d-Orn}-{Orn}-Gly-{d-Orn}-Trp-Thr-Ile-Gly-Ser (Lactone: Thr9-Ser12)
-
シーケンスの短縮
4-Methylhexanoyl-{d-Asn}-{d-Tyr}-{d-Trp}-{d-Orn}-{Orn}-G-{d-Orn}-WTIGS (Lactone: Thr9-Ser12)
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
溶剤 & 溶解度
H2O : ≥ 50 mg/mL
* "≥" means soluble, but saturation unknown.
純度とドキュメンテーション
-
データシート (276 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
取扱説明書 (2659 KB)
参考文献
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Brevicidine TFA 関連分類
HY-P10519A 関連分類
Powered by Bioz